Borggreve, A. S. http://orcid.org/0000-0002-5385-6449
,
Mook, S.
Verheij, M.
Mul, V. E. M.
Bergman, J. J.
Bartels-Rutten, A.
ter Beek, L. C.
Beets-Tan, R. G. H.
Bennink, R. J.
van Berge Henegouwen, M. I.
Brosens, L. A. A.
Defize, I. L.
van Dieren, J. M.
Dijkstra, H.
van Hillegersberg, R.
Hulshof, M. C.
van Laarhoven, H. W. M.
Lam, M. G. E. H.
van Lier, A. L. H. M. W.
Muijs, C. T.
Nagengast, W. B.
Nederveen, A. J.
Noordzij, W.
Plukker, J. T. M.
van Rossum, P. S. N.
Ruurda, J. P.
van Sandick, J. W.
Weusten, B. L. A. M.
Voncken, F. E. M.
Yakar, D.
Meijer, G. J.
Funding for this research was provided by:
KWF Kankerbestrijding (10291)
Article History
Received: 13 September 2018
Accepted: 3 October 2018
First Online: 20 October 2018
Ethics approval and consent to participate
: The study has been approved by the Medical Ethics Review Committee of the University Medical Center Utrecht (version 3.0, 04-04-2018, 17–941, NL62881.041.17) and covers all clinical sites involved in the study. The following 4 high-volume centers in the Netherlands participate in the study: University Medical Center Utrecht, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, University Medical Center Groningen and Amsterdam University Medical Centers. Recruitment of patients started in April 2018. Written, voluntary, informed consent to participate in the study will be obtained from all patients.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.